These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1168 related articles for article (PubMed ID: 31159869)

  • 21. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
    Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
    J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells.
    Dietz LL; Furman NT; Larsen TV; Daugaard TF; Thomsen EA; Keller JL; Aagaard L; Sorensen BS; Nielsen AL
    J Immunother; 2022 Nov-Dec 01; 45(9):379-388. PubMed ID: 36036966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
    Stutvoet TS; Kol A; de Vries EG; de Bruyn M; Fehrmann RS; Terwisscha van Scheltinga AG; de Jong S
    J Pathol; 2019 Sep; 249(1):52-64. PubMed ID: 30972766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
    Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
    Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D
    J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
    Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
    Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
    Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
    Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.
    Luo YH; Yang YP; Chien CS; Yarmishyn AA; Adekunle Ishola A; Chien Y; Chen YM; Tsai PH; Lin TW; Wang ML; Chiou SH
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
    Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
    Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.